Precision BioSciences (NASDAQ:DTIL) Earns Buy Rating from HC Wainwright

Precision BioSciences (NASDAQ:DTIL)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $60.00 price objective on the stock.

Separately, BMO Capital Markets upgraded Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective on the stock in a research note on Friday.

Precision BioSciences Price Performance

Shares of DTIL stock opened at $4.50 on Friday. The firm has a fifty day moving average of $6.15 and a two-hundred day moving average of $8.30. The firm has a market cap of $34.52 million, a P/E ratio of 75.01 and a beta of 1.51. Precision BioSciences has a 1-year low of $3.61 and a 1-year high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC raised its stake in Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 702,069 shares of the company’s stock after acquiring an additional 68,943 shares during the period. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 as of its most recent SEC filing. 37.99% of the stock is currently owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.